Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
CAS RN: 82419-36-1 | Product Number: O0403
Ofloxacin

Purity: >98.0%(T)(HPLC)
- 9-Fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid
Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
---|---|---|---|---|---|
5G |
$92.00
|
1 | 1 | ≥40 |
|
25G |
$295.00
|
1 | Contact Us | 10 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | O0403 |
Purity / Analysis Method | >98.0%(T)(HPLC) |
Molecular Formula / Molecular Weight | C__1__8H__2__0FN__3O__4 = 361.37 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
Condition to Avoid | Light Sensitive |
CAS RN | 82419-36-1 |
Reaxys Registry Number | 3657947 |
PubChem Substance ID | 172089006 |
Merck Index (14) | 6771 |
MDL Number | MFCD00226105 |
Appearance | White to Light yellow powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Neutralization titration) | min. 98.0 % |
Melting Point | 263 °C |
Maximum Absorption Wavelength | 326(H2O) nm |
RTECS# | UU8815500 |
HS Number | 2934.99.9001 |
References
- Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
- Quinolones in 2005: an update (a review)
- Moxifloxacin [M2479], ofloxacin, sparfloxacin [S0896], and ciprofloxacin [C2227, C2510] against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy
- Synthesis and antibacterial activities of optically active ofloxacin
- Direct determination of four fluoroquinolones, enoxacin [E0762], norfloxacin [N0817], ofloxacin, and ciprofloxacin [C2227, C2510], in pharmaceuticals and blood serum by HPLC
- Determination of ofloxacin, norfloxacin [N0817], and ciprofloxacin [C2227, C2510] in sewage by selective solid-phase extraction, liquid chromatography with fluorescence detection, and liquid chromatography-tandem mass spectrometry
References
- Quinolones in 2005: an update
- In vitro and in vivo activity of DL-8280, a new oxazine derivative
- Fourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibiotics
- Direct determination of four fluoroquinolones, enoxacin, norfloxacin, ofloxacin, and ciprofloxacin, in pharmaceuticals and blood serum by HPLC
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.